CureVac N.V. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 53.76 million compared to EUR 67.42 million a year ago. Net loss was EUR 260.17 million compared to EUR 249.03 million a year ago.

Basic loss per share from continuing operations was EUR 1.18 compared to EUR 1.32 a year ago. Diluted loss per share from continuing operations was EUR 1.18 compared to EUR 1.32 a year ago.